Abivax SA (ABVX)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 77.95 |
|---|---|
| 52-week range | 60.45 – 139.00 |
| Return, 1 month / 3 months | −14.3% / −32.5% |
| Return, 1 year / 3 years | +2.4% / +779.8% |
| Trend | Below its 200-day average |
| RSI (14) | 37 |
| Volatility (1 year) | 88.4% |
| Worst drawdown (1 year) | -48.4% |
| Average daily value traded | 12.76M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Abivax is a clinical-stage biopharmaceutical company based in Paris, France. It focuses on developing oral therapies that modulate the immune system to treat chronic inflammatory diseases. Its main drug candidate is being studied for inflammatory bowel disease, including ulcerative colitis, and the company also has earlier-stage work in antiviral medicines. Its customers are ultimately patients and healthcare providers, while its development work is carried out with clinical investigators and partners in the medical field.
On this site Abivax SA appears as a stock on the Euronext Paris (France), code ABVX, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Abivax SA (ABVX) trades on the Euronext Paris in France. It last closed at EUR 77.95 on 19 October 2026.
Its price-based Market X-Ray is 40 out of 100 (a weak price profile), ranking 431 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 2.4% and over the last three months it fell 32.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 28 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -22.0% | ||
| From 52-week high | -42.3% | ||
| Momentum | 40 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -32.5% | ||
| 6-month return | -20.4% | ||
| 12-month return, skipping the last month | 19.6% | ||
| Stability (higher is calmer) | 21 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 88.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -48.4% | ||
| Liquidity | 91 · Strong | Trades actively. | |
| Average daily value traded | 12.76M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −0.3% |
|---|---|
| 1 month | −14.3% |
| 3 months | −32.5% |
| 6 months | −20.4% |
| 1 year | +2.4% |
| 3 years | +779.8% |
| 5 years | +184.5% |
Signals
| 50-day / 200-day average | 92.35 / 99.98 |
|---|---|
| Golden / death cross (60 days) | Death, 16 days ago |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 4.14 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.